Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
("Mediclinic", the "Company", or the "Group")
FOR IMMEDIATE RELEASE
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION.
MEDICLINIC IRREVOCABLE UNDERTAKING WITH RESPECT TO THE RECOMMENDED CASH OFFER BY RAMSAY HEALTH CARE LIMITED ("RAMSAY") FOR SPIRE HEALTHCARE GROUP PLC ("SPIRE")
Mediclinic notes the announcement on
Mediclinic confirms it has provided an irrevocable undertaking to vote in favour of the Offer. The irrevocable undertaking will cease to be binding if, amongst other things, a competing offer for Spire is made that provides for an amount or value of consideration which is not less than 10 per cent greater than
The funds received from the sale of Mediclinic's shareholding in Spire will reduce leverage, providing additional financial flexibility to deliver Mediclinic's strategic goals including the pursuit of further growth opportunities.
Mediclinic is one of the largest private healthcare providers across
Morgan Stanley is acting as financial adviser to Mediclinic in relation to the potential transaction.
The information contained in this announcement is inside information. The person responsible for arranging the release of this announcement is
This announcement contains certain forward-looking statements relating to the business of the Company and its subsidiaries, including with respect to the progress, timing and completion of the Group's development; the Group's ability to treat, attract and retain patients and clients; its ability to engage consultants and healthcare practitioners and to operate its business and increase referrals; the integration of prior acquisitions; the Group's estimates for future performance and its estimates regarding anticipated operating results; future revenue; capital requirements; shareholder structure; and financing. In addition, even if the Group's actual results or development are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of the Group's results or developments in the future. In some cases, forward-looking statements can be identified by words such as "could", "should", "may", "expects", "aims", "targets", "anticipates", "believes", "intends", "estimates", or similar. These forward-looking statements are based largely on the Group's current expectations as of the date of this announcement and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the Group's expectations could be affected by, among other things, uncertainties involved in the integration of acquisitions or new developments; changes in legislation or the regulatory regime governing healthcare in
The Group is providing the information in this announcement as of this date, and disclaims any intention to, and makes no undertaking to, publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Mediclinic is a diversified international private healthcare services group, established in
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of its markets.
The Company's primary listing is on the
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group based in the
+44 (0)20 3786 8181
+44 (0)20 3727 1000
+27 (0)21 487 9000
Registered address: 6th Floor,
Joint corporate brokers:
JSE sponsor (
NSX sponsor (
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the